Inhibitors for coronavirus

1. A method for treatment of COVID-19 caused by SARS-COV-1, SARS-CoV-2 (Covid-19) and MERS-CoV, and variants within each, in a mammalian subject in need therefore, comprising administering to the subject an effective amount of a pyrroloquinazoline of the following formulae:

wherein

X 1 and X 2 are CH and joined together by a double bond;

Y is independently C;

Z is CH 2 ;

R 1 is 2-trifluorophenyl, 2-methylphenyl, 4-nitrophenyl, ethylene, 2-fluorophenyl, pyridine-3-yl, pyridine-2-yl, pyridine-4-yl or cyclohexyl;

R 2 is H or methyl;

R 3 is H;

R 4 and R 5 are independently amino groups;

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

2. The method of claim 1 wherein said pyrroloquinazoline comprises 7-(2-(trifluoromethyl)benzyl)-7H-pyrrolo[3,2 -f]quinazoline-1,3-diamine.

3. The method of claim 1 wherein said pyrroloquinazoline comprises 7-(2-methylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

4. The method of claim 1 wherein said pyrroloquinazoline comprises 4-((1,3-diamino-8-methyl-7H-pyrrolo [3,2-f]quinazolin-7-yl)methyl)benzonitrile.

5. The method of claim 1 wherein said pyrroloquinazoline comprises 7-allyl-7H-pyrrolo[3,2-fiquinazoline-1,3-diamine.

6. The method of claim 1 wherein said pyrroloquinazoline comprises 7-(2-(fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

7. The method of claim 1 wherein said pyrroloquinazoline comprises 7-(pyridin-3-ylmethyl)-7H-pyrrolo [3,2-f]quinazoline-1,3-diamine.

8. The method of claim 1 wherein said pyrroloquinazoline comprises 7-(pyridin-4-ylmethyl)-7H-pyrrolo[3,2-fiquinazoline-1,3-diamine.

9. The method of claim 1 wherein said pyrroloquinazoline comprises 7-(pyridin-2-ylmethyl)-7H-pyrrolo[3,2-fiquinazoline-1,3-diamine.

10. The method of claim 1 wherein said pyrroloquinazoline comprises 7-(cyclohexylmethyl)-7H-pyrrolo[3,2-fiquinazoline-1,3-diamine.